Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 5, 2020

Interferences in the measurement of circulating phosphate: a literature review

Valentina Molinaris, Mario G. Bianchetti, Gregorio P. Milani ORCID logo, Sebastiano A.G. Lava, Roberto Della Bruna, Giacomo D. Simonetti and Pietro B. Faré

Abstract

Background

Inorganic phosphate in blood is currently determined by the reaction with molybdate. This report aims at reviewing conditions underlying spuriously altered levels of circulating inorganic phosphate.

Content

A systematic search of the Excerpta Medica, the National Library Database and the Web of Science database was conducted without language restriction from the earliest publication date available through January 31, 2020.

Summary

For the analysis, 80 reports published in English (n = 77), French (n = 1), German (n = 1) and Spanish (n = 1) were retained. Well-documented pseudohyperphosphatemia was observed in individuals exposed to liposomal amphotericin, in patients affected by a gammopathy, in patients with hyperlipidemia and in patients with hyperbilirubinemia. An unexplained elevated inorganic phosphate level sometimes provided a clue to the diagnosis of a gammopathy. Well-documented cases of pseudohypophosphatemia were observed in patients on large amounts of intravenous mannitol. Finally, pseudohypophosphatemia was occasionally observed on treatment with liposomal amphotericin and in patients with a gammopathy.

Outlook

In order to avoid unnecessary testing and treatment, the phenomenon of spuriously altered inorganic phosphate should be recognized. An unexplained hyperphosphatemia may provide a clue to the diagnosis of a gammopathy or a severe hyperlipidemia.


Corresponding author: Dr. Sebastiano A.G. Lava, MD MSc, Pediatric Cardiology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois (CHUV), and University of Lausanne, 1010 Lausanne, Switzerland

  1. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: Authors state no conflict of interest.

References

1. Manghat P, Sodi R, Swaminathan R. Phosphate homeostasis and disorders. Ann Clin Biochem 2014;51:631–56.10.1177/0004563214521399Search in Google Scholar

2. Bell RD, Doisy EA. Rapid colorimetric methods for the determination of phosphorus in urine and blood. J Biol Chem 1920;44:55–67.10.1016/S0021-9258(18)86271-8Search in Google Scholar

3. Young DS, Thomas DW, Friedman RB, Pestaner LC. Effects of drugs on clinical laboratory tests. Clin Chem 1972;18:1041–303.10.1093/clinchem/18.10.1041Search in Google Scholar

4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65–94.10.7326/0003-4819-151-4-200908180-00136Search in Google Scholar PubMed

5. Jackson JL, Kuriyama A, Anton A, Choi A, Fournier JP, Geier AK, et al. The accuracy of Google translate for abstracting data from non-English-language trials for systematic reviews. Ann Intern Med 2019;171:677–9.10.7326/M19-0891Search in Google Scholar PubMed

6. Lane JW, Rehak NN, Hortin GL, Zaoutis T, Krause PR, Walsh TJ. Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Chim Acta 2008;387:145–9.10.1016/j.cca.2007.08.008Search in Google Scholar PubMed PubMed Central

7. Mendoza D, Connors S, Lane C, Stehnach S. Liposomal amphotericin B as a cause of pseudohyperphosphatemia. Clin Infect Dis 2008;46:645–6.10.1086/527041Search in Google Scholar PubMed

8. Jensen GM, Bunch TH, Wolf S, Laybourne S. Erroneous determination of hyperphosphatemia (“pseudohyperphosphatemia”) in sera of patients that have been treated with liposomal amphotericin B (AmBisome). Clin Chim Acta 2010;411:1900–5.10.1016/j.cca.2010.07.017Search in Google Scholar PubMed

9. Knoderer CA, Knoderer HM. Hyperphosphatemia in pediatric oncology patients receiving liposomal amphotericin B. J Pediatr Pharmacol Ther 2011;16:87–91.10.5863/1551-6776-16.2.87Search in Google Scholar PubMed PubMed Central

10. Miller MM, Johnson PN, Hagemann TM, Carter SM, Miller JL. Pseudohyperphosphatemia in children treated with liposomal amphotericin B. Am J Health Syst Pharm 2014;71:1462–8.10.2146/ajhp130613Search in Google Scholar PubMed

11. Bohm NM, Hoover KC, Wahlquist AE, Zhu Y, Velez JC. Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B. Antimicrob Agents Chemother 2015;59:6816–23.10.1128/AAC.01306-15Search in Google Scholar PubMed PubMed Central

12. Albersen M, Bökenkamp A, Schotman H, Smetsers S. Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia. Pediatr Nephrol 2019;34:625–9.10.1007/s00467-018-4097-xSearch in Google Scholar PubMed PubMed Central

13. Suchin EJ, Cizman B, Connolly BR, DiBattista WJ, Agus ZS. Pseudohyperphosphatemia in a hyperphosphatemic hemodialysis patient. Am J Kidney Dis 2002;40:E18.10.1053/ajkd.2002.36351Search in Google Scholar PubMed

14. Ball CL, Tobler K, Ross BC, Connors MR, Lyon ME. Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. Clin Chem Lab Med 2004;42:107–8.10.1515/CCLM.2004.021Search in Google Scholar PubMed

15. Cachat F, Bardy D, Durussel C, Di Paolo E. Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter. Pediatr Nephrol 2006;21:301–2.10.1007/s00467-005-2088-1Search in Google Scholar PubMed

16. Schiller B, Virk B, Blair M, Wong A, Moran J. Spurious hyperphosphatemia in patients on hemodialysis with catheters. Am J Kidney Dis 2008;52:617–20.10.1053/j.ajkd.2008.03.033Search in Google Scholar PubMed PubMed Central

17. Sombolos K, Bamichas G, Hatsiou V, Fragidis S, Rizos A, Natse T, et al. Alteplase as hemodialysis catheter locking solution and spurious hyperphosphatemia. J Vasc Access 2011;12:269.10.5301/JVA.2011.6220Search in Google Scholar PubMed

18. Senthilkumaran S, Menezes RG, Jayaraman S, Thirumalaikolundusubramanian P. Pseudohyperphosphatemia due to contamination with heparin: a case for caution. Indian J Nephrol 2014;24:409–10.10.4103/0971-4065.133040Search in Google Scholar PubMed PubMed Central

19. Leehey DJ, Daugirdas JT, Ing TS, Reid RW. Spurious hyperphosphatemia due to hyperlipidemia. Arch Intern Med 1985;145:743–4.10.1001/archinte.1985.00360040177039Search in Google Scholar

20. Tetiker T. Pseudohyperphosphatemia resulting from hyperlipoproteinemia. Turk J Endocrinol Metab 1999;3:93–4.Search in Google Scholar

21. Khan TA, Arif A, Seamonds B, Doyle AM. Spurious hyperphosphatemia related to severe hyperbilirubinemia in patients with end-stage liver disease. Clin Nephrol 2014;82:368–71.10.5414/CN108350Search in Google Scholar PubMed

22. Randall AG, Garcia-Webb P, Beilby JP. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction. Ann Clin Biochem 1990;27:345–52.10.1177/000456329002700411Search in Google Scholar

23. Steen G, Vermeer HJ, Naus AJ, Goevaerts B, Agricola PT, Schoenmakers CH. Multicenter evaluation of the interference of hemoglobin, bilirubin and lipids on Synchron LX-20 assays. Clin Chem Lab Med 2006;44:413–9.10.1515/CCLM.2006.067Search in Google Scholar

24. Ali D, Sacchetto É, Reigner A, Le Carrer D, Orsonneau JL, Delaroche O, et al. Interférences de la lipémie et de l’ictère sur le dosage de 24 paramètres biochimiques. Ann Biol Clin (Paris) 2015;73:671–89.Search in Google Scholar

25. Nicolay A, Lorec AM, Gomez G, Portugal H. Icteric human samples: Icterus index and method of estimating an interference-free value for 16 biochemical analyses. J Clin Lab Anal 2018;32:e22229.10.1002/jcla.22229Search in Google Scholar

26. Lacher DA, Nally JV. Falsely elevated values for serum phosphorus in multiple myeloma. Clin Chem 1986;32:1232.10.1093/clinchem/32.6.1232aSearch in Google Scholar

27. Sonnenblick M, Eylath U, Brisk R, Eldad C, Hershko C. Paraprotein interference with colorimetry of phosphate in serum of some patients with multiple myeloma. Clin Chem 1986;32:1537–9.10.1093/clinchem/32.8.1537Search in Google Scholar

28. Busse JC, Gelbard MA, Byrnes JJ, Hellman R, Vaamonde CA. Pseudohyperphosphatemia and dysproteinemia. Arch Intern Med 1987;147:2045–6 [Erratum in: Arch Intern Med 1988;148:302].10.1001/archinte.1987.00370110173027Search in Google Scholar

29. Pettersson T, Hortling L, Teppo AM, Tötterman KJ, Fyhrquist F. Phosphate binding by a myeloma protein. Acta Med Scand 1987;222:89–91.10.1111/j.0954-6820.1987.tb09934.xSearch in Google Scholar

30. Adler SG, Laidlaw SA, Lubran MM, Kopple JD. Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 1988;11:260–3.10.1016/S0272-6386(88)80159-8Search in Google Scholar

31. McCloskey EV, Galloway J, Morgan MA, Kanis JA. Pseudohyperphosphataemia in multiple myeloma. Br Med J 1989;299:1381–2.10.1136/bmj.299.6712.1381Search in Google Scholar PubMed PubMed Central

32. Weinberg J, Adler AJ. Spurious hyperphosphatemia in patients with dysglobulinemia. Miner Electrolyte Metab 1989;15:185–6.Search in Google Scholar

33. Bakker AJ, Bosma H, Christen PJ. Influence of monoclonal immunoglobulins in three different methods for inorganic phosphorus. Ann Clin Biochem 1990;27:227–31.10.1177/000456329002700308Search in Google Scholar PubMed

34. Duly E, Lemon L, Trinick TR. Influence of monoclonal immunoglobulins on methods for inorganic phosphorous. Ann Clin Biochem 1991;28:196.10.1177/000456329102800217Search in Google Scholar

35. Mandry JM, Posner MR, Tucci JR, Eil C. Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin. Cancer 1991;68:1092–4.10.1002/1097-0142(19910901)68:5<1092::AID-CNCR2820680531>3.0.CO;2-ISearch in Google Scholar

36. McClure D, Lai LC, Cornell C. Pseudohyperphosphataemia in patients with multiple myeloma. J Clin Pathol 1992;45:731–2.10.1136/jcp.45.8.731Search in Google Scholar

37. Grateau G, Bachmeyer C, Tauléra O, Sarfati G, Cremer G, Séréni D. Pseudohyponatremia and pseudohyperphosphatemia in a patient with human immunodeficiency virus infection. Nephron 1993;64:640.10.1159/000187414Search in Google Scholar

38. Bowles SA, Tait RC, Jefferson SG, Gilleece MH, Haeney MR. Characteristics of monoclonal immunoglobulins that interfere with serum inorganic phosphate measurement. Ann Clin Biochem 1994;31:249–54.10.1177/000456329403100306Search in Google Scholar

39. Cohen AM, Magazanik A, van-der Lijn E, Shaked P, Levinsky H. Pseudohyperphosphataemia incidence in an automatic analyzer. Eur J Clin Chem Clin Biochem 1994;32:559–61.Search in Google Scholar

40. Oren S, Feldman A, Turkot S, Lugassy G. Hyperphosphatemia in multiple myeloma. Ann Hematol 1994;69:41–3.10.1007/BF01757346Search in Google Scholar

41. Larner AJ. Pseudohyperphosphatemia. Clin Biochem 1995;28:391–3.10.1016/0009-9120(95)00013-YSearch in Google Scholar

42. Savory DJ, Pearce CJ. Paraprotein interference causing pseudohyperphosphataemia: evaluation of an improved methodology. Ann Clin Biochem 1995;32:498–501.10.1177/000456329503200511Search in Google Scholar

43. Zaman Z, Sneyers L, Van Orshoven A, Blanckaert N, Mariën G. Elimination of paraprotein interference in determination of plasma inorganic phosphate by ammonium molybdate method. Clin Chem 1995;41:609–14.10.1093/clinchem/41.4.609Search in Google Scholar

44. Mavrikakis M, Vaiopoulos G, Athanassiades P, Antoniades L, Papamichael C, Dimopoulos MA. Pseudohyperphosphatemia in multiple myeloma. Am J Hematol 1996;51:178–9.10.1002/(SICI)1096-8652(199602)51:2<178::AID-AJH22>3.0.CO;2-DSearch in Google Scholar

45. Rodríguez-Cuartero A, Pérez-Blanco FJ, Salas-Galán A, Miras-Parra FJ. Pseudohyperphosphatemia in Waldenström’s macroglobulinemia. Clin Nephrol 1999;52:265–6.Search in Google Scholar

46. Jamil MG, Abdel-Raheem MM, Potti A, Levitt R. Pseudohyperphosphatemia associated with Waldenström’s macroglobulinemia. Am J Hematol 2000;65:329.10.1002/1096-8652(200012)65:4<329::AID-AJH20>3.0.CO;2-6Search in Google Scholar

47. Barutçuoglu B, Parildar Z, Mutaf I, Habif S, Bayindir O. Spuriously elevated inorganic phosphate level in a multiple myeloma patient. Clin Lab Haematol 2003;25:271–4.10.1046/j.1365-2257.2003.00524.xSearch in Google Scholar

48. Cheikhrouhou Abdelmoula L, Amira C, Chaabouni L, Kchir MM, Zouari R. Hyperphosphatemia in multiple myeloma. Joint Bone Spine 2003;70:541–2.10.1016/S1297-319X(03)00161-1Search in Google Scholar

49. Marcu CB, Hotchkiss M. Pseudohyperphosphatemia in a patient with multiple myeloma. Conn Med 2004;68:71–2.Search in Google Scholar

50. Sinclair D, Smith H, Woodhead P. Spurious hyperphosphataemia caused by an IgA paraprotein: a topic revisited. Ann Clin Biochem 2004;41:119–24.10.1258/000456304322879999Search in Google Scholar

51. Stratta P, Canavese C, Quaglia M, Lazzarich E, Morellini V, Brustia M, et al. A patient with unexplained hyperphosphataemia. Nephrol Dial Transplant 2006;21:2664–6.10.1093/ndt/gfl306Search in Google Scholar

52. El Bouchti I, Belkhou A, Younsi R, El Asan S. Pseudohyperphosphatemia in multiple myeloma. Joint Bone Spine 2007;74:206–7.10.1016/j.jbspin.2006.07.004Search in Google Scholar

53. Izzedine H, Camous L, Bourry E, Azar N, Leblond V, Deray G. Make your diagnosis. Multiple myeloma-associated with spurious hyperphosphatemia. Kidney Int 2007;72:1035–6.10.1038/sj.ki.5002485Search in Google Scholar

54. Kiki I, Gundogdu M, Kaya H. Spuriously high phosphate level which is promptly resolved after plasmapheresis in a patient with multiple myeloma. Transfus Apher Sci 2007;37:157–9.10.1016/j.transci.2007.07.005Search in Google Scholar

55. Lee Y, Koo T, Yi JH, Choi JH, Han SW, Park IK, et al. Pseudohyperphosphatemia in a patient with multiple myeloma. Electrolyte Blood Press 2007;5:131–5.10.5049/EBP.2007.5.2.131Search in Google Scholar

56. Loh TP, Saw S, Sethi SK. Hyperphosphatemia in a 56-year-old man with hypochondrial pain. Clin Chem 2010;56:892–5.10.1373/clinchem.2009.136895Search in Google Scholar

57. Lovekar S, Chen JL. A 90-year-old man with hyperphosphatemia. Am J Kidney Dis 2011;57:342–6.10.1053/j.ajkd.2010.07.017Search in Google Scholar PubMed

58. Aiyer R, Kazory A. Spurious hyperphosphatemia: a case for caution. Am J Kidney 2012;60:1050–1.10.1053/j.ajkd.2012.09.005Search in Google Scholar PubMed

59. Toutkaboni MP, Taheri ZM, Mohammadi F, Seifollahi L, Sabeti S. Hyperphosphatemia in a patient with respiratory problems. Lab Med 2012;43:291–3.10.1309/LMPQ55MG8GXKOFMLSearch in Google Scholar

60. Amalnath SD, Dubashi B. Pseudohyperphosphatemia in Waldenstrom’s macroglobulinemia. Indian J Nephrol 2013;23:465–6.10.4103/0971-4065.120351Search in Google Scholar PubMed PubMed Central

61. Aeberhard N, Schild C, Rodondi N, Roten-Joss C, Tänzler K. Phosphat(verw)irrungen: tatsächlich «Hyper» oder nur «Pseudo»? Praxis (Bern 1994) 2014;103:1203–6.10.1024/1661-8157/a001792Search in Google Scholar PubMed

62. Chakraborty S, Sen S, Gupta D, Ghosh SS, Sawant P, Das M. Spurious hyperphosphatemia in a case of multiple myeloma. Indian J Clin Biochem 2014;29:250–2.10.1007/s12291-013-0368-2Search in Google Scholar PubMed PubMed Central

63. Diehl M, Carrizo CL, Fantl D, Jiménez GB. Hipofosfatemia e hiperfosfatemia espurias en una paciente con mieloma múltiple. Actual Osteol 2014;10:91–6.Search in Google Scholar

64. Vaidya GN, Bhattad VB, Aggarwal A. Pseudohyperphosphatemia in multiple myeloma: a commonly misdiagnosed phenomenon. Sci Postprint 2014;1:e00039.10.14340/spp.2014.12C0002Search in Google Scholar

65. Khan TA, Arif A, Seamonds B, Doyle AM. Spurious hyperphosphatemia related to severe hyperbilirubinemia in patients with end-stage liver disease. Clin Nephrol 2014;82:368–71.10.5414/CN108350Search in Google Scholar PubMed

66. Chakraborty S, Kallner A. Measurement of serum-phosphate concentration in immunoglobulin G monoclonal gammopathy after PEG-precipitation. Clin Chim Acta 2015;440:211–3.10.1016/j.cca.2014.11.028Search in Google Scholar PubMed

67. Maden M, Pamuk GE, Asoglu V, Pamuk ON. The rapid resolution of pseudohyperphosphatemia in an IGAκ multiple myeloma patient after therapy with a bortezomib-containing regimen: report of the first case. J Cancer Res Ther 2015;11:1043.10.4103/0973-1482.157333Search in Google Scholar PubMed

68. Talebi S, Gomez N, Iqbal Z, Pekler G, Visco F, Hassen GW, et al. Spurious hyperphosphatemia: a diagnostic and therapeutic challenge. Am J Med 2016;129:e15–6.10.1016/j.amjmed.2015.11.024Search in Google Scholar

69. Francis ER, Chen F, Kidacki M, Miller R, Alkhasoneh M, Talamo G, et al. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma. Clin Chim Acta 2018;487:306–8.10.1016/j.cca.2018.10.016Search in Google Scholar

70. Kritmetapak K, Dumrongsukit S, Jinchai J, Wongprommek P. Pseudohyperphosphatemia in a patient with relapsed multiple myeloma after bone marrow transplantation: a case report. Clin Case Rep 2019;7:1426–9.10.1002/ccr3.2264Search in Google Scholar

71. Boud’hors C, Le Gallo M, Orvain C, Larcher F, Gardembas M, Augusto JF, et al. Hyperphosphatemia and multiple myeloma: keep calm and control first. Am J Med 2019 Nov 9. pii: S0002-9343(19)30965-9. doi: 10.1016/j.amjmed.2019.10.022. [Epub ahead of print].Search in Google Scholar

72. Lambertucci JR, Otoni A, Rodrigues VL. Pseudohyperkalemia and pseudohyperphosphatemia after splenectomy in hepatosplenic schistosomiasis mansoni. Rev Soc Bras Med Trop 2008;41:692.10.1590/S0037-86822008000600028Search in Google Scholar

73. Donhowe JM, Freier EF, Wong ET, Steffes MW. Factitious hypophosphatemia related to mannitol therapy. Clin Chem 1981;27:1765–9.10.1093/clinchem/27.10.1765Search in Google Scholar

74. McCoy MT, Aguanno JJ, Ritzmann SE. Interferences of mannitol with phosphate determination. Am J Clin Pathol 1982;77:468–70.10.1093/ajcp/77.4.468Search in Google Scholar

75. Eisenbrey AB, Mathew R, Kiechle FL. Mannitol interference in an automated serum phosphate assay. Clin Chem 1987;33:2308–9.10.1093/clinchem/33.12.2308Search in Google Scholar

76. Caras JA. Spurious hypophosphatemia associated with multiple myeloma. Endocr Pract 1997;3:135–6.10.4158/EP.3.3.135Search in Google Scholar

77. Loghman-Adham M, Walton D, Iverius PH, Deiss A, Knight JA, Cheung AK. Spurious hypophosphatemia in a patient with multiple myeloma. Am J Kidney Dis 1997;30:571–5.10.1016/S0272-6386(97)90319-XSearch in Google Scholar

78. Malhotra A, Koduli PR. Polyclonal hyperglobulinemia and spurious hypophosphatemia. Ann Intern Med 1999;131:314.10.7326/0003-4819-131-4-199908170-00026Search in Google Scholar PubMed

79. Weisbord SD, Chaudhuri A, Blauth K, DeRubertis FR. Monoclonal gammopathy and spurious hypophosphatemia. Am J Med Sci 2003;325:98–100.10.1097/00000441-200302000-00007Search in Google Scholar PubMed

80. Kerr S, Kindt J, Daram SR. Hypophosphatemia associated with paraproteinemia: a case report and review of the literature. WMJ 2007;106:490–3.Search in Google Scholar

81. Polak R, Huisman A, Sikma MA, Kersting S. Spurious hypokalaemia and hypophosphataemia due to extreme hyperleukocytosis in a patient with a haematological malignancy. Ann Clin Biochem 2010;47:179–81.10.1258/acb.2010.009170Search in Google Scholar PubMed

82. Mao Z, Ong AC. Spurious hypophosphatemia associated with monoclonal paraproteinemia. QJM 2012;105:693–6.10.1093/qjmed/hcr104Search in Google Scholar PubMed

83. Saad M, Moussaly E, Ibrahim U, Atallah JP, Forte F, Odaimi M. Multiple myeloma and hypophosphatemia. Am J Kidney Dis 2016;68:A17–20.10.1053/j.ajkd.2016.04.019Search in Google Scholar PubMed

84. Mays JA, Greene DN, Poon A, Merrill AE. Pseudohypophosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Biochem 2017;50:967–71.10.1016/j.clinbiochem.2017.05.016Search in Google Scholar PubMed

85. Feinstein S, Becker-Cohen R, Rinat C, Frishberg Y. Hyperphosphatemia is prevalent among children with nephrotic syndrome and normal renal function. Pediatr Nephrol 2006;21:1406–12.10.1007/s00467-006-0195-2Search in Google Scholar PubMed

86. Sexton DJ, Kinsella SM, Eustace JA. Serum phosphate varies with degree of proteinuria in nephrotic syndrome and is associated with elevated pulse wave velocity. J Nephrol 2013;26:540–8.10.5301/jn.5000186Search in Google Scholar PubMed

87. de Seigneux S, Wilhelm-Bals A, Courbebaisse M. On the relationship between proteinuria and plasma phosphate. Swiss Med Wkly 2017;147:w14509.10.4414/smw.2017.14509Search in Google Scholar PubMed

88. Andenmatten F, Bianchetti MG, Gerber HA, Zimmermann A, Meregalli P, Lüthy C, et al. Outcome of idiopathic childhood nephrotic syndrome. A 20-year experience. Scand J Urol Nephrol 1995;29:15–9.10.3109/00365599509180533Search in Google Scholar PubMed

89. Plebani M, Lippi G. Improving diagnosis and reducing diagnostic errors: the next frontier of laboratory medicine. Clin Chem Lab Med 2016;54:1117–8.10.1515/cclm-2016-0217Search in Google Scholar PubMed

Received: 2020-03-08
Accepted: 2020-05-14
Published Online: 2020-06-05
Published in Print: 2020-11-26

©2020 Walter de Gruyter GmbH, Berlin/Boston